Literature DB >> 20526397

Two lung masses with different responses to pemetrexed.

Kwang Young Park1, Jae Wook Jung, Seung Bum Nam, Ho Jin Lee, Hyo Seok Kim, Yoon Hee Choi, Jae Cheol Lee.   

Abstract

We described here a patient who had two lung masses. Although the two masses had the same histology and a similar good response to initial chemotherapy with gemcitabine and carboplatin, the response to pemetrexed as a second-line treatment was different after re-growth of the tumors. These two lung masses could have originated from different clones or they could have progressed through different paths of molecular pathogenesis after metastasis, which would lead to different tumor characteristics, including their chemosensitivity. Regardless of their pathogenetic mechanisms, it seems important to recognize that tumors with the same histology that develop in one patient can have different responses to drugs.

Entities:  

Keywords:  Drug resistance; Lung neoplasms; Neoplasms, multiple primary; Pemetrexed

Mesh:

Substances:

Year:  2010        PMID: 20526397      PMCID: PMC2880697          DOI: 10.3904/kjim.2010.25.2.213

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  11 in total

1.  Synchronous multiple primary lung cancers with different response to gefitinib.

Authors:  Baek-Yeol Ryoo; Im Il Na; Sung Hyun Yang; Jae Soo Koh; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  Lung Cancer       Date:  2006-06-19       Impact factor: 5.705

2.  Predicting cancer drug response by proteomic profiling.

Authors:  Yan Ma; Zhenyu Ding; Yong Qian; Xianglin Shi; Vince Castranova; E James Harner; Lan Guo
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  [Intrapulmonary metastasis in resected cases of pulmonary carcinoma].

Authors:  I Kinoshita; T Matsubara; K Nakagawa; E Tsuchiya
Journal:  Nihon Kyobu Geka Gakkai Zasshi       Date:  1983-11

4.  Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.

Authors:  Noriyuki Nakatsu; Yoko Yoshida; Kanami Yamazaki; Tomoki Nakamura; Shingo Dan; Yasuhisa Fukui; Takao Yamori
Journal:  Mol Cancer Ther       Date:  2005-03       Impact factor: 6.261

5.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Synchronous primary lung cancers: prevalence in surgical material and clinical implications.

Authors:  F A Carey; S C Donnelly; W S Walker; E W Cameron; D Lamb
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

8.  Survival following resection for second and third primary lung cancers.

Authors:  D J Mathisen; R J Jensik; L P Faber; C F Kittle
Journal:  J Thorac Cardiovasc Surg       Date:  1984-10       Impact factor: 5.209

9.  In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.

Authors:  Axel-Rainer Hanauske; Ulrike Eismann; Olaf Oberschmidt; Heike Pospisil; Steve Hoffmann; Hartmut Hanauske-Abel; Doreen Ma; Victor Chen; Paolo Paoletti; Clet Niyikiza
Journal:  Invest New Drugs       Date:  2007-05-30       Impact factor: 3.850

Review 10.  Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness.

Authors:  Hisayuki Kobayashi
Journal:  Recent Results Cancer Res       Date:  2003
View more
  3 in total

1.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Authors:  Zhi-Yong Chen; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Xue-Ning Yang; Zhi-Hong Chen; Jin-Ji Yang; Qing Zhou; Hong-Hong Yan; She-Juan An; Hua-Jun Chen; Ben-Yuan Jiang; Tony S Mok; Yi-Long Wu
Journal:  Oncologist       Date:  2012-06-06

2.  The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.

Authors:  Hyun Joo Jang; Ji Woong Cho; Bumjung Park; Hyun Chang Choi; Hyeong Su Kim; Jung Han Kim
Journal:  J Cancer       Date:  2015-01-05       Impact factor: 4.207

3.  Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.

Authors:  Soong Goo Jung; Jung Han Kim; Hyeong Su Kim; Kyoung Ju Kim; Ik Yang
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.